Agios Pharmaceuticals (AGIO) EBITDA Margin (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly EBITDA Margin came in at 247.07% in Q2 2026, up 77305.0% YoY from N/an in Q2 2025, and up 53.41% on a QoQ basis from 530.34% in Q1 2026.
Powered by 
Analysis
Agios Pharmaceuticals (AGIO) EBITDA Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 14 years of EBITDA Margin data on file, last reported at 247.07% in Q2 2026.
- Quarterly EBITDA Margin rose 77305.0% year-over-year to 247.07% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 466.78% (up 66235.0% YoY) and the FY2025 annual result came in at 873.87%, up 29260.0% from the prior year.
- EBITDA Margin rose to 247.07% in Q2 2026, from 530.34% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 247.07% in Q2 2026 to a low of 12156.85% in Q1 2022.
- A 5-year average of 1881.65% and a median of 1225.13% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin surged 1054136 bps — and 2025, when it plunged 9763 bps.
- Tracing AGIO's EBITDA Margin over 5 years: stood at 2300.97% in 2022, then soared by 35 bps to 1496.23% in 2023, then advanced by 22 bps to 1165.3% in 2024, then jumped by 48 bps to 608.89% in 2025, then soared by 59 bps to 247.07% in 2026.
- The last three EBITDA Margin figures came in at 247.07% (Q2 2026), 530.34% (Q1 2026), and 608.89% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.56 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.35 Bn | 32.04 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.38 Bn | 27.54 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Agios Pharmaceuticals | 1.97 Bn | 1.97 Bn | 41.75 Mn | -247.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -247.07% |
| Mar 31, 2026 | -530.34% |
| Dec 31, 2025 | -608.89% |
| Sep 30, 2025 | -907.37% |
| Jun 30, 2025 | -1,020.12% |
| Mar 31, 2025 | -1,221.97% |
| Dec 31, 2024 | -1,165.30% |
| Sep 30, 2024 | -1,146.93% |
| Jun 30, 2024 | -1,228.29% |
| Mar 31, 2024 | -1,124.34% |
| Dec 31, 2023 | -1,496.23% |
| Sep 30, 2023 | -1,363.66% |
| Jun 30, 2023 | -1,396.01% |
| Mar 31, 2023 | -1,615.49% |
| Dec 31, 2022 | -2,300.97% |
| Sep 30, 2022 | -2,590.73% |
| Jun 30, 2022 | -1,749.19% |
| Mar 31, 2022 | -12,156.85% |
| Dec 31, 2020 | -209.86% |
| Sep 30, 2020 | -231.34% |